ff02e85e-2f87-4832-aaea-3322db33c57a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.430
- FATTY_ACID_METABOLISM+0.390
- CHOLESTEROL_HOMEOSTASIS+0.370
- INTERFERON_ALPHA_RESPONSE+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350
- INTERFERON_GAMMA_RESPONSE+0.320
- PEROXISOME+0.320
- ALLOGRAFT_REJECTION+0.310
- IL6_JAK_STAT3_SIGNALING+0.290
- COMPLEMENT+0.280
Top 10 suppressed
- MITOTIC_SPINDLE-0.340
- HEDGEHOG_SIGNALING-0.320
- WNT_BETA_CATENIN_SIGNALING-0.300
- MYC_TARGETS_V2-0.210
- G2M_CHECKPOINT-0.160
- MYOGENESIS-0.120
- UV_RESPONSE_DN-0.120
- APICAL_JUNCTION-0.090
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.080
- UNFOLDED_PROTEIN_RESPONSE-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-49-4494-01A-01R-1206-07 | — | cohortA1 | 0.898 |
| 2 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.849 |
| 3 | SRR1321853 | GTEX | — | 0.847 |
| 4 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.847 |
| 5 | TCGA-05-5425-01A-02R-1628-07 | — | cohortA4 | 0.844 |
| 6 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.836 |
| 7 | TCGA-34-5241-01A-01R-1443-07 | — | cohortSQ1 | 0.834 |
| 8 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.831 |
| 9 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.829 |
| 10 | SRR1078879 | GTEX | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |